Free gift on orders $400+ Ā· pick BPC-157, NAD+ 500MG, MOTS-C 10MG & more•Complimentary 2-day shipping over $250• Same-day dispatch before 12 PM MT• New batches made in the USA• ≄99% average purity Ā· independent U.S. lab testing• Free gift on orders $400+ Ā· pick BPC-157, NAD+ 500MG, MOTS-C 10MG & more•Complimentary 2-day shipping over $250• Same-day dispatch before 12 PM MT• New batches made in the USA• ≄99% average purity Ā· independent U.S. lab testing•
0
Trust built by transparency. Scan the vial, read the lab’s own report.

Compound comparison

AOD-9604 vs SLU-PP-332Fat-Tissue Peptide vs Muscle-Focused Small Molecule

Updated Nov 1, 20264 min readResearch use only
Research overview4 min readUpdated Nov 1, 2026

AOD-9604 is a 16-amino-acid peptide taken from the end of the growth hormone molecule, studied since the 1990s for its effects on fat tissue. SLU-PP-332 is a synthetic small molecule described in 2023 that activates the estrogen-related receptors (ERRs) and switches on an exercise-like gene program in muscle. This guide compares them side by side.

All compounds discussed are sold for laboratory research use only. This page summarizes published research and is not guidance for human or veterinary use.

At a glance

AOD-9604 SLU-PP-332
Class Synthetic peptide; modified growth hormone fragment Synthetic small molecule; receptor agonist
Based on Human growth hormone residues 177-191, plus an added tyrosine A synthetic aryl acylhydrazone built to activate ERRs
Length / size 16 amino acids, one disulfide loop Small molecule, 290.3 g/mol
Target No direct receptor identified Estrogen-related receptors (ERRα, β, γ), most potent at ERRα
Main tissue studied Fat tissue Skeletal muscle (also heart)
Origin Australian growth hormone research; metabolic studies from 2000 Saint Louis University; full description 2023
Rogue Compounds format Lyophilized vial Capsules

Fat tissue versus muscle

The clearest difference is where each compound is studied. AOD-9604 research measures what happens inside fat tissue: how fat cells break down stored fat (lipolysis) and build new fat (lipogenesis). SLU-PP-332 research centers on skeletal muscle, where activating ERRα pushes muscle toward the oxidative profile normally produced by aerobic exercise.

They also differ in how well their mechanisms are understood. SLU-PP-332 was designed for a known target and acts on it directly. No receptor that binds AOD-9604 directly has been identified, so its proposed mechanism is based on downstream measurements in fat tissue.

AOD-9604: the growth hormone fragment

AOD-9604 came out of Australian research on what was called the lipolytic domain of growth hormone. AOD-9604 was designed as an optimized version of that sequence, and its metabolic effects in rodents were described in 2000 (Ng et al., 2000).

The differences between the two mouse types were read as evidence that the β3 pathway contributes to the peptide’s effects (Heffernan et al., 2001a). For more, see the AOD-9604 research overview.

SLU-PP-332: the exercise-mimetic receptor agonist

SLU-PP-332 was described in 2023 as a synthetic agonist of all three estrogen-related receptors, with the highest potency at ERRα. In a muscle cell line it increased mitochondrial function and cellular respiration. In mice it increased oxidative type IIa muscle fibers, switched on an ERRα-dependent acute aerobic exercise gene program and improved exercise endurance (Billon et al., 2023).

A separate group reported that ERR agonists including SLU-PP-332 preserved oxidative metabolism and protected the heart in a mouse model of pressure-overload heart failure (Xu et al., 2024). For more, see the SLU-PP-332 research overview.

Where their research overlaps

  • Fat oxidation: studies of both compounds reported increased fat oxidation, measured through different tissues and methods.
  • Energy use: both are studied on the energy-use side of metabolism rather than for reducing food intake.

How researchers choose between them

  • To study fat-cell lipolysis and lipogenesis, AOD-9604 is the relevant compound, since its research centers on adipose tissue.
  • To study muscle and exercise signaling, SLU-PP-332 is the relevant compound, since its main effects are on muscle fiber type and endurance.
  • For a defined molecular target, SLU-PP-332 is the clearer tool, since AOD-9604’s direct target is still unknown.

What the research does not show

There are no studies comparing AOD-9604 and SLU-PP-332 head to head or testing them together.

Verify what you’re working with

The two products are tested differently. AOD-9604 reports show HPLC purity and identity; capsule reports for SLU-PP-332 confirm identity and fill weight. Our guide on how to read a peptide COA walks through both, and every batch we sell is in the COA Library.

View AOD-9604 on Rogue Compounds Ā· View SLU-PP-332 on Rogue Compounds

Frequently asked questions

What is the difference between AOD-9604 and SLU-PP-332?

AOD-9604 is a 16-amino-acid peptide derived from the end of human growth hormone and studied mainly in fat tissue. SLU-PP-332 is a small synthetic molecule that activates the estrogen-related receptors and is studied mainly in muscle.

Is AOD-9604 a growth hormone?

No. It is a short fragment based on residues 177-191 of human growth hormone, designed to study the hormone’s metabolic domain separately from the full molecule.

Why is SLU-PP-332 called an exercise mimetic?

In mice, it switched on the same ERRα-dependent gene program seen after aerobic exercise, increased oxidative muscle fibers and improved endurance.

Are AOD-9604 and SLU-PP-332 for human use?

No. Rogue Compounds sells both as research chemicals, not for human use. They are for laboratory research only.

References

  1. Natera SH, Jiang WJ, Ng FM. Biochem Mol Biol Int. 1994;33:1011-1021. PMID 7987248
  2. Ng FM, et al. Horm Res. 2000;53(6):274-278. PMID 11146367
  3. Heffernan M, et al. Endocrinology. 2001;142(12):5182-5189. PMID 11713213
  4. Heffernan MA, et al. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PMID 11673763
  5. Billon C, et al. ACS Chem Biol. 2023;18(4):756-771. PMID 36988910
  6. Billon C, et al. J Pharmacol Exp Ther. 2024;388(2):232-240. PMID 37739806
  7. Xu W, et al. Circulation. 2024;149(3):227-250. PMID 37961903

Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.

Research bundles

Compounds researchers often order together, 5% off as a set. Every vial ships with its batch COA.

See all research bundles →

Trust built by transparency. Scan the vial, read the lab’s own report.

Research peptides & laboratory compounds. Built by researchers. For researchers.

Support

Disclaimer

The statements provided herein have not been assessed by the Food and Drug Administration. These products are not designed to diagnose, treat, cure, or prevent any disease. Rogue Compounds does not operate as a compounding pharmacy or chemical compounding facility as defined under 503A/503B of the Federal Food, Drug, and Cosmetic Act. The products available on this website are intended for research use only and are not suitable for human or animal consumption.

© 2026 Rogue Compounds. All rights reserved.

For research use only